Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Simcere Pharmaceutical Group Limited ( (HK:2096) ) has provided an update.
Simcere Pharmaceutical Group has voluntarily withdrawn and plans to promptly resubmit its New Drug Application in China for rademikibart, an innovative IL-4Rα-targeting monoclonal antibody for atopic dermatitis co-developed with Connect Biopharma, as part of a strategic optimization of its commercialization plan. Phase 3 data showed rapid onset and strong long-term efficacy, with EASI-75, EASI-90 and IGA 0/1 response rates climbing to 96.6%, 85.3% and 87.1% by week 52, underscoring the drug’s potential to strengthen Simcere’s position in the competitive inflammatory and autoimmune therapeutics market and support its broader innovation-led growth strategy.
The most recent analyst rating on (HK:2096) stock is a Buy with a HK$16.30 price target. To see the full list of analyst forecasts on Simcere Pharmaceutical Group Limited stock, see the HK:2096 Stock Forecast page.
More about Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited is an innovation- and R&D-driven pharmaceutical company that has established a State Key Laboratory of Neurology and Oncology Drug Development. It focuses on therapeutic areas including neuroscience, oncology, autoimmune diseases and anti-infective treatments, targeting future high clinical-need indications through in-house research and strategic collaborations with innovative companies and institutes.
Average Trading Volume: 6,852,824
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$33.17B
For a thorough assessment of 2096 stock, go to TipRanks’ Stock Analysis page.